Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

11Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Cite

CITATION STYLE

APA

Woestenberg, P. J., King, A. J., Van Benthem, B. H. B., Leussink, S., Van Der Sande, M. A. B., Hoebe, C. J. P. A., & Bogaards, J. A. (2020). Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands. Journal of Infectious Diseases, 221(8), 1280–1285. https://doi.org/10.1093/infdis/jiz187

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free